Registro:

Referencias:

• Guidelines for the use of antiretroviral agents in adults and adolescents, , http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0, Department of Human and Health Services, USAUSA, (accessed March 10, 2014)
• Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia (2003) N Engl J Med, 348, pp. 2186-2195. , TORO 2 Study Group
• Hicks, C.B., Cahn, P., Cooper, D.A., Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials (2006) Lancet, 368, pp. 466-475. , for the RESIST investigator group
• Clotet, B., Bellos, N., Mollina, J.-M., Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials (2007) Lancet, 369, pp. 1169-1178. , for the POWER 1 and 2 study groups
• Raltegravir with optimized background therapy for resistant HIV-1 infection (2008) N Engl J Med, 359, pp. 339-354. , BENCHMRK Study Teams
• Maraviroc for previously treated patients with R5 HIV-1 infection (2008) N Engl J Med, 359, pp. 1429-1441. , MOTIVATE Study Teams
• Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study (2013) Lancet, 381, pp. 2091-2099. , SECOND-LINE Study Group
• Paton, N.I., Kityo, C., Hoppe, A., A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial (2014) N Engl J Med, 371, pp. 234-247. , for the EARNEST Trial Group
• Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, , http://www.who.int/hiv/pub/guidelines/arv2013/download/en/, WHO, (accessed March 15, 2014)
• Harries, A.D., Zachariah, R., van Oosterhout, J.J., Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives (2010) Lancet Infect Dis, 10, pp. 60-65
• Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings (2009) J Infect Dis, 200, pp. 687-697. , EuroSIDA Study Group
• Hosseinipour, M.C., van Oosterhout, J.J., Weigel, R., The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy (2009) AIDS, 23, pp. 1127-1134
• Amin, J., Boyd, M.A., Kumarasamy, N., for the SECOND-LINE study group. Raltegravir non-inferior to nuleos(t)ide-based regimens in SECOND-LINE therapy with lopinavir/ritonavir over 96 weeks: a randomised (2014), open label study. Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, March 3-6, Abstr 237; Genotypic Resistance Interpretation Algorithm version 6.3.1, , http://sierra2.stanford.edu/sierra/servlet/JSierra, Stanford University HIV Drug Resistance Database, (accessed March 10, 2014)
• Chesney, M.A., Ickovics, J.R., Chambers, D.B., Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG) (2000) AIDS Care, 12, pp. 255-266
• Deeks, S.G., Wrin, T., Liegler, T., Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia (2001) N Engl J Med, 344, pp. 472-480
• Nijhuis, M., Deeks, S., Boucher, C., Implications of antiretroviral resistance on viral fitness (2001) Curr Opin Infect Dis, 14, pp. 23-28
• Deeks, S.G., Hoh, R., Neilands, T.B., Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection (2005) J Infect Dis, 192, pp. 1537-1544
• Thirumurthy, H., Siripong, N., Vreeman, R.C., Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting (2012) AIDS, 26, pp. 2399-2403
• Hosseinipour, M.C., Kumwenda, J.J., Weigel, R., Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline (2010) HIV Med, 11, pp. 510-518
• Johnston, V., Cohen, K., Wiesner, L., Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch (2014) J Infect Dis, 209, pp. 711-720
• Molina, J.M., Lamarca, A., Andrade-Villanueva, J., Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study (2012) Lancet Infect Dis, 12, pp. 27-35
• Cahn, P., Andrade-Villanueva, J., Arribas, J.R., Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial (2014) Lancet Infect Dis, 14, pp. 572-580
• Katzenstein, D.A., HIV RNA and genotype in resource-limited settings: can we do better? (2014) Clin Infect Dis, 58, pp. 110-112
• Panidou, E.T., Trikalinos, T.A., Ioannidis, J.P., Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis (2004) AIDS, 18, pp. 2153-2161
• Eron, J.S., Young, B., Cooper, D.A., Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials (2010) Lancet, 375, pp. 396-407. , for the SWITCHMRK 1 and 2 investigators
• Hurt, C.B., Sebastian, J., Hicks, C.B., Eron, J.J., Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012 (2014) Clin Infect Dis, 58, pp. 423-431
• Raffi, F., Babiker, A.G., Richert, L., Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial (2014) Lancet, 384, pp. 1942-1951. , for the NEAT001/ANRS143 study group
• Hosseinipour, M.C., Gupta, R.K., Van Zyl, G., Eron, J.J., Nachega, J.B., Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings (2013) J Infect Dis, 207, pp. S49-S56
• Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant hiv-1: 24-week results of the phase III VIKING-3 study (2014) J Infect Dis, 210, pp. 354-362. , VIKING-3 Study Group
• Johnson, V.A., Calvez, V., Gunthard, H.F., Update on the drug resistance mutations in HIV-1: March 2013 (2013) Top Antivir Med, 21, pp. 6-14

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------